BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98

Benzinga · 2d ago
BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.